Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (351-360 of 706) with videos related to

Pageof 71
Sort By:
Critical Pathways in Cardiology|March 11, 2010
Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement programChristopher P Cannon, James W Hoekstra, David M Larson, et al.
Clinical Cardiology|January 24, 2014
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trialJonathan W Waks, Marc S Sabatine, Christopher P Cannon, et al.
Journal of the American Heart Association|November 20, 2017
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Eri Toda Kato, Christopher P Cannon, Michael A Blazing, et al.
Clinical Cardiology|April 14, 2018
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndromeMatthew A Cavender, William B White, Yuyin Liu, et al.
Atherosclerosis|June 30, 2019
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trialsKausik K Ray, Antonio J Vallejo-Vaz, Henry N Ginsberg, et al.
Journal of the American College of Cardiology|August 1, 2009
Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines ProgramTodd M Brown, Adrian F Hernandez, Vera Bittner, et al.
Circulation|February 13, 2003
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromesJames A de Lemos, David A Morrow, Marc S Sabatine, et al.
JAMA Cardiology|November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker StudyDaniel Lindholm, Stefan K James, Katja Gabrysch, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 12, 2006
Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndromeRaphaelle Dumaine, C Michael Gibson, Sabina A Murphy, et al.
American Journal of Nephrology|June 12, 2022
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV TrialDavid Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Pageof 71

Showing results (351-360 of 706) with videos related to

Sort By:
Pageof 71
Critical Pathways in Cardiology|March 11, 2010
Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement programChristopher P Cannon, James W Hoekstra, David M Larson, et al.
Clinical Cardiology|January 24, 2014
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trialJonathan W Waks, Marc S Sabatine, Christopher P Cannon, et al.
Journal of the American Heart Association|November 20, 2017
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Eri Toda Kato, Christopher P Cannon, Michael A Blazing, et al.
Clinical Cardiology|April 14, 2018
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndromeMatthew A Cavender, William B White, Yuyin Liu, et al.
Atherosclerosis|June 30, 2019
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trialsKausik K Ray, Antonio J Vallejo-Vaz, Henry N Ginsberg, et al.
Journal of the American College of Cardiology|August 1, 2009
Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines ProgramTodd M Brown, Adrian F Hernandez, Vera Bittner, et al.
Circulation|February 13, 2003
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromesJames A de Lemos, David A Morrow, Marc S Sabatine, et al.
JAMA Cardiology|November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker StudyDaniel Lindholm, Stefan K James, Katja Gabrysch, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 12, 2006
Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndromeRaphaelle Dumaine, C Michael Gibson, Sabina A Murphy, et al.
American Journal of Nephrology|June 12, 2022
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV TrialDavid Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Pageof 71